ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Triumvira raises funds for improved T-cell therapies

by Michael McCoy
August 28, 2020 | APPEARED IN VOLUME 98, ISSUE 33

 

Triumvira Immunologics has completed a $55 million series A funding round led by Northpond Ventures and Leaps by Bayer, a Bayer investment arm. The Austin, Texas–based firm was founded in 2015 to create immuno-oncology therapies by engineering patients’ T cells with its T-cell antigen coupler (TAC), a multidomain molecule that guides T cells selectively to tumor cells. Triumvira says TAC modification yields better T cells than those created with current engineering approaches, which typically are not effective against solid tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment